Explore Stanford technologies available for licensing:

Stanford researchers have developed a conductive nanoporous powder technology that dramatically enhances electrode stability and efficiency for fuel cells and electrolyzers.

Stanford researchers have developed a novel therapeutic approach for neurodegenerative diseases by targeting endoplasmic reticulum (ER) stress in neurons using CHOP inhibitors, with significant potential for development into first-in-class neuroprotective drugs for neurodegene

The Stanford team has developed a method to dynamically control the topography of nano-scale surfaces using soft, responsive polymers, enabling new ways to actively shape the spectral, angular and polarization properties of light in response to electrical and chemical stimuli

Stanford researchers have developed a non-viral, homology-independent method for precise targeted DNA insertions into T-cells using electroporation and CRISPR/Cas9, enabling cost-effective production of CAR T-cells for T-cell therapies.

Researchers in Prof. Crystal Mackall's laboratory at Stanford University are focused on translational research related to cancer immunotherapy, including basic T-cell function and tumor immunology.

Stanford scientists in Dr. Michael Lin's lab have established the use of B-cell reducing agents to improve an oncolytic virus (OV) therapy to rewire cancer signaling while limiting the production of antibodies against the virus in mouse studies.

Heart failure is a complex cardiovascular disease that affects 26 million people worldwide and is characterized by the inability of the heart to pump blood effectively, leading to a decline in its normal functions.

Stanford researchers have created an optimized stuffer sequence derived from the human BMP-10 3'UTR to enhance the packaging efficiency, productivity, and safety of recombinant adeno-associated virus (rAAV) vectors in gene therapy applications.

Stanford researchers have developed a method of versatile packaging and release of drug substances using ultrasound induced release.

Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.

Stanford researchers have demonstrated clinical proof of concept that a real-time biofeedback system can reduce pain and slow joint degeneration in patients with movement disorders such as knee osteoarthritis.

Stanford researchers have developed a method of reducing pulmonary hypertension (PH) in mammals by targeting FHIT (Fragile Histidine Triad), a gene not previously linked to PH but consistently reduced in blood of patients with pulmonary arterial hypertension (PAH).

Mechanical engineers at Stanford have patented a soft robot with a vine-like structure capable of growing over 100 times in length.

Stanford researchers have patented a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).

Aging-associated mitochondrial dysfunction (mito-dysfunction) affects every cell system in our body. Mito-dysfunction includes reduced quality of mitochondrial DNA (mtDNA), irregular generation of reactive oxygen species, and membrane potential.